Common Contracts
4 similar Registration Rights Agreement contracts by NKGen Biotech, Inc.
SECURITIES PURCHASE AGREEMENTRegistration Rights Agreement • April 5th, 2024 • NKGen Biotech, Inc. • Biological products, (no disgnostic substances) • Delaware
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 1, 2024, by and between NKGEN BIOTECH, INC., a Delaware corporation, with headquarters located at 3001 Daimler Street, Santa Ana, CA, 92705 (the “Company”), and Sandia Investment Management LP on behalf of Diametric True Alpha Market Neutral Master Fund LP and Diametric True Alpha Enhanced Market Neutral Master Fund, with its address at 201 Washington Street, Boston, MA 02108 (the “Buyer”).
SECURITIES PURCHASE AGREEMENTRegistration Rights Agreement • April 5th, 2024 • NKGen Biotech, Inc. • Biological products, (no disgnostic substances) • Delaware
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 1, 2024, by and between NKGEN BIOTECH, INC., a Delaware corporation, with headquarters located at 3001 Daimler Street, Santa Ana, CA, 92705 (the “Company”), and AJB CAPITAL INVESTMENTS LLC, a Delaware limited liability company, with its address at 4700 Sheridan Street, Suite J, Hollywood, FL 33021 (the “Buyer”).
SECURITIES PURCHASE AGREEMENTRegistration Rights Agreement • March 27th, 2024 • NKGen Biotech, Inc. • Biological products, (no disgnostic substances) • Delaware
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 21, 2024, by and between NKGEN BIOTECH, INC., a Delaware corporation, with headquarters located at 3001 Daimler Street, Santa Ana, CA, 92705 (the “Company”), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its address at 1040 First Avenue, Suite 190, New York, NY 10022 (the “Buyer”).
SECURITIES PURCHASE AGREEMENTRegistration Rights Agreement • March 27th, 2024 • NKGen Biotech, Inc. • Biological products, (no disgnostic substances) • Delaware
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 26, 2024, by and between NKGEN BIOTECH, INC., a Delaware corporation, with headquarters located at 3001 Daimler Street, Santa Ana, CA, 92705 (the “Company”), and Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP, and Meteora Strategic Capital, LLC (collectively, the “Buyer”).
